Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States (vol 39, pg 313, 2016)

被引：0
|
作者：
Gandra, Shravanthi R.
机构：
来源：
CLINICAL CARDIOLOGY | 2016年 / 39卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：621 / 621
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
    Gandra, Shravanthi R.
    Villa, Guillermo
    Fonarow, Gregg C.
    Lothgren, Mickael
    Lindgren, Peter
    Somaratne, Ransi
    van Hout, Ben
    [J]. CLINICAL CARDIOLOGY, 2016, 39 (06) : 313 - 320
  • [2] COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
    Gandra, S. R.
    Villa, G.
    Fonarow, G.
    Lothgren, M.
    Lindgren, P.
    Somaratne, R.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A3 - A3
  • [3] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Yuansheng Wan
    Jinyu Liu
    Xiaolian Zhan
    Yu Zhang
    Ruxu You
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [4] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Wan, Yuansheng
    Liu, Jinyu
    Zhan, Xiaolian
    Zhang, Yu
    You, Ruxu
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [5] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [6] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
  • [7] Peripheral arterial Disease LDL-C and cardiovascular Risk significantly lowering with Evolocumab
    Unger-Hunt, Lydia
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2018, 11 (02): : 68 - 70
  • [8] Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
    Lindgren, P.
    Hagstrom, E.
    Van Hout, B.
    Villa, G.
    Urbich, M.
    Sandelin, R.
    Svensson, M. Eriksson
    Fonarow, G. C.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 681 - 681
  • [9] COST-EFFECTIVENESS OF AGGRESSIVE LDL-C LOWERING FOR ACUTE CORONARY SYNDROM PATIENTS IN FRANCE
    de Pouvourville, G.
    Gueron, B.
    de Gendre, A. Solesse
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 206 - 206
  • [10] LDL-C LOWERING EFFICACY OF EVOLOCUMAB (AMG 145) COULD REDUCE APHERESIS IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS IN GERMANY
    Villa, G.
    Schmid, T.
    Lothgren, M.
    Michailov, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A504 - A504
12345